{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:50:43Z","timestamp":1790754643184,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":868,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Genzyme Corporation"},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shire HGT"},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shire HGT"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.jacc.2010.11.018","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T05:03:02Z","timestamp":1298437382000},"page":"1093-1099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"title":["Cardiovascular Events in Patients With Fabry Disease"],"prefix":"10.1016","volume":"57","author":[{"given":"Manesh R.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cizmarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilkka","family":"Kantola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Strotmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Tallaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Chien","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Beitner-Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ademola","family":"Abiose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2010.11.018_bib1","series-title":"The Metabolic Bases of Inherited Disease","first-page":"3733","article-title":"Alpha-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.jacc.2010.11.018_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2010.11.018_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jacc.2010.11.018_bib4","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2010.11.018_bib5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2010.11.018_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jacc.2010.11.018_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CRD.0b013e31818adc50","article-title":"Fabry disease: cardiac manifestations and therapeutic options","volume":"17","author":"Pierre-Louis","year":"2009","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.jacc.2010.11.018_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2009.08.002","article-title":"Cardiac challenges in patients with Fabry disease","volume":"141","author":"Weidemann","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2010.11.018_bib9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ultrasmedbio.2008.10.010","article-title":"Heart valve involvement in Fabry cardiomyopathy","volume":"35","author":"Weidemann","year":"2009","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jacc.2010.11.018_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.amjcard.2005.05.033","article-title":"Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease","volume":"96","author":"Shah","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.11.018_bib11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1203\/PDR.0b013e318183f132","article-title":"Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry","volume":"64","author":"Hopkin","year":"2008","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jacc.2010.11.018_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.11.018_bib13","series-title":"Regression and ANOVA: An Integrated Approach Using SAS Software","first-page":"231","article-title":"Section 11.5.5., selecting the best model","author":"Muller","year":"2002"},{"key":"10.1016\/j.jacc.2010.11.018_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ajmg.a.30123","article-title":"Inheritance of most X-linked traits is not dominant or recessive, just X-linked","volume":"129A","author":"Dobyns","year":"2004","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.jacc.2010.11.018_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2010.11.018_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2010.11.018_bib17","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2010.11.018_bib18","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2010.11.018_bib19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.clinthera.2009.09.008","article-title":"Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis","volume":"31","author":"Kampmann","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacc.2010.11.018_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/10976640600605002","article-title":"The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease","volume":"8","author":"Moon","year":"2006","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.jacc.2010.11.018_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3960\/jslrt.49.121","article-title":"An autopsy case of Fabry\u2019s disease with cardiac manifestations","volume":"49","author":"Suzuki","year":"2009","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.jacc.2010.11.018_bib22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/HCO.0b013e3283383d1d","article-title":"Myocardial scar as arrhythmia risk in patients with hypertrophic cardiomyopathy","volume":"25","author":"Amado","year":"2010","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacc.2010.11.018_bib23","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/j.ejrad.2009.12.012","article-title":"Correlation between myocardial fibrosis and the occurrence of atrial fibrillation in hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study","volume":"75","author":"Pujadas","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jacc.2010.11.018_bib24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1253\/circj.CJ-09-0723","article-title":"Significance of maximal and regional left ventricular wall thickness in association with arrhythmic events in patients with hypertrophic cardiomyopathy","volume":"74","author":"Puntmann","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2010.11.018_bib25","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.amjcard.2005.11.087","article-title":"Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry\u2019s cardiomyopathy","volume":"97","author":"Beer","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2010.11.018_bib26","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease","volume":"69","author":"Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2010.11.018_bib27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","article-title":"Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa","volume":"94","author":"Hughes","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2010.11.018_bib28","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.018_bib29","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2010.11.018_bib30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2010.11.018_bib31","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2010.11.018_bib32","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2010.11.018_bib33","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/ncpneph0806","article-title":"Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults","volume":"4","author":"Ortiz","year":"2008","journal-title":"Nat Clin Pract Nephrol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710048369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109710048369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:42:25Z","timestamp":1760013745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109710048369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0735109710048369"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2010.11.018","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Events in Patients With Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2010.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}